// Dwight H. Owen 1 , Andrew J. Alexander 2 , Bhavana Konda 1 , Lai Wei 3 , Jessica A. Hemminger 4 , Carl R. Schmidt 5 , Sherif R.Z. Abdel-Misih 5 , Mary E. Dillhoff 5 , Jennifer A. Sipos 6 , Lawrence S. Kirschner 6 and Manisha H. Shah 1 1 Division of Medical Oncology, Department of Internal Medicine, The Ohio State University Comprehensive Cancer Center, Columbus, OH, USA 2 Division of Infectious Disease, Department of Internal Medicine, The Ohio State University Comprehensive Cancer Center, Columbus, OH, USA 3 Center for Biostatistics, The Ohio State University Comprehensive Cancer Center, Columbus, OH, USA 4 Department of Pathology, The Ohio State University Comprehensive Cancer Center, Columbus, OH, USA 5 Division of Surgical Oncology, Department of Surgery, The Ohio State University Comprehensive Cancer Center, Columbus, OH, USA 6 Division of Endocrinology, Diabetes & Metabolism, Department of Internal Medicine, The Ohio State University Comprehensive Cancer Center, Columbus, OH, USA Correspondence to: Manisha H. Shah, email: Manisha.Shah@osumc.edu Keywords: neuroendocrine tumors; MGMT; temozolomide; capecitabine; immunohistochemistry Received: March 21, 2017 Accepted: October 05, 2017 Published: October 24, 2017 ABSTRACT Recent advances in the treatment of neuroendocrine tumors (NET), including the combination regimen of capecitabine and temozolomide (CAPTEM), have mostly focused on grade 1 and 2 pancreatic neuroendocrine tumors (pNET). We undertook a retrospective review of 38 patients with advanced NET treated with CAPTEM, including patients with non-pancreatic tumors as well as grade 2 and 3 tumors. O 6 -methylguanine DNA methyltransferase (MGMT) expression was assessed as a predictive biomarker. We found that CAPTEM demonstrated activity in patients with all grades and in pNET and non-pNET. Median progression free survival (mPFS) was 13.0 months (95% CI: 5.6-17.0) and median overall survival (mOS) 29.3 months (95% CI 17.7 - 45.3). Among evaluable patients, there were 11 (38%) partial responses, 15 (52%) stable disease, and 3 (10%) progressive disease for a disease control rate of 90%. A higher rate of partial responses occurred in patients whose tumors had low levels of MGMT expression (63%) compared to intermediate-high (17%) (p=0.19). Our results show that CAPTEM therapy is active in patients with NET including in previously treated patients and in those with poorly-differentiated histology. We observed a trend towards increased response rate, median PFS, and median OS in patients whose tumors had low MGMT protein expression.
No takes yet. Share an insight, caveat, or question.
Owen et al. (2017) studied this question.